Showing posts with label United Health Care. Show all posts
Showing posts with label United Health Care. Show all posts

United Health Care’s Genetic Testing: Includes More Than You’d Think



Today’s Managing Health Care Costs Indicator is $25 billion




That’s the upper end of what a new white paper from United Health Care says genetic testing might cost in 2021.  The UHC data shows that the insurance giant spent $500 billion on genetic testing in 2010. 

I was pretty shocked when I saw that Medicaid beneficiaries had a higher rate of genetic testing than those with commercial (employer sponsored) insurance or those on Medicare.  Huh?   Does it make sense that an insurance plan focused on economically-disadvantaged young moms, the disabled who often suffer from major mental illness and long-time nursing home residents would have the highest rate of genetic testing? 

Only if the definition of genetic testing is expansive.  A genetic test here is defined as any test that uses genetics to get an answer. The overwhelming majority of tests are likely laboratory studies to rule out sexually transmitted disease (chlamydia, gonorrhea, and HIV).  Those tests aren’t nearly as expensive * as the tests of an individual’s genome to detect heritable diseases, or the tests of a cancer’s genome to determine susceptibility to a chemotherapy agent.  They often replace non-genetic tests that took longer, required more difficult sample-gathering, or were less accurate.  

I think it’s more valuable to focus on the more expensive genetic tests that are being used to personalize medicine – and consider the tests for sexually transmitted disease (not highly individualized) just as we treat other diagnostic tests.






Click images to enlarge. Source 



UHC’s recommendations on how to approach genetic testing from a policy perspective make sense to me. The recommendations are on pages 5 and 6; I’ve rephrased them

- Insure confidentiality
- Do comparative effectiveness research 
- Pay for the actual value of a test (rather than an inflated initial amount with upward adjustments) 
- Transparent coding and reporting
- Better regulation of lab companies doing genetic tests – especially “laboratory developed tests,” which right now the white paper says have “minimal oversight.” 
- Train doctors and health professionals so that they can give accurate (and good) advice

* Note you can purchase 20-pack tests for chlamydia for about $20 per test. 

Two case studies on why it's hard to constrain health care costs

Two articles in the New York Times on Saturday demonstrate the difficulty we have constraining health care costs.  We have trouble agreeing to cuts in home health care when independent analysis shows overly generous margins (on average), and we have trouble rejecting payment for a cancer drug that costs $36,000 a month, and has not been shown to have clinical benefit.

A front page articl follows a home health nurse making rounds in rural Caribou, Maine. (Not coincidentally, Maine has two Republican senators most likely to buck their party and vote for health care reform. One of them, Susan Collins, was born in Caribou.)   Cuts in home health care payments could force large layoffs in this community – which would deprive isolated rural seniors from a low-tech lifeline, and could lead to more hospitalizations. 

MedPAC recommended sharp cuts in home health care, as its analysis showed that on the average the margin in home care was too high.  (Of course, averages obscure many situations – and rural home care nurses who are only able to see five patients a day due to travel distances are very different than urban home care nurses who can walk from client to client!)   This information from the Dartmouth Atlas shows that overall Maine has far less home health expenses than expected, even though more highly populated southern Maine uses more resources than average. 

National Average:   434.5 services/1000
Maine Average:   350.3 services/1000
Maine uses $14,600,000 less resources on home health services than the national average

The front page of the business section  of the paper highlighted Folotyn, a drug newly approved for peripheral T cell lymphoma.  This disease is aggressive, strikes under 6000 in the US each year, and there is no other effective therapy.  Folotyn has been shown to shrink tumors in 27% of patients treated; it was not shown to prolong life. Here’s a direct quote from the article.

...Dr. Lee N. Newcomer, senior vice president for oncology at the big insurer UnitedHealthcare, called the price of Folotyn “unconscionable.” He said that Folotyn alone would cost as much as UnitedHealthcare now typically spends in total to treat a lymphoma patient from diagnosis until death. That median expenditure now, he said, is $87,000 for a little over a year of treatments.


But Dr. Newcomer said insurers would be obligated to pay for Folotyn because there were no alternatives.

So there you have it.  Home care probably is paid too much on average – but there are areas where resources spent are inadequate.  We focus on these areas in our public discussion.   Oncology care costs too much, but with no alternative for this new medication, we will keep writing checks.


The Future of Health Plans

It’s been a bad week for health insurers – most of them lost substantial value in the stock market this week after the Obama budget was released, causing investor worry due to lower payments to Medicare HMOs.  Further, the economic funk and rising unemployment will lead to a decrease in the number of Americans insured through the private marketplace, and continuing “buy downs” from comprehensive coverage to policies with higher deductibles and copays.  These plans are also far less profitable to the insurers.

 

Perhaps the biggest threat to health insurers is the possibility that health care reform could allow those under 65 without disabilities to “buy into” Medicare.   Proponents argue that Medicare has low transactional costs, obtains high levels of provider discounts and offers excellent choice to its patients.  How does Medicare achieve these economies?

(1)Medicare spends less than commercial health plans on administration as a percentage of premium – in part because it need do no marketing to attract enrollees, and in part because the premiums are so much higher for the Medicare population than they are for those under 65 (so administration costs shrink as a percentage of total costs.)

(2)Medicare does not do “network contracting” as private health plans do.  All licensed physicians who have not been convicted of fraud are eligible to join – and to do so they must agree to follow a uniform set of Medicare rules and to accept Medicare reimbursement rates. 

(3)Hospitals have long collected data showing that they lose money on Medicare, and make this up by obtaining high rates from commercial insurance plans.  It’s a classic example of cost-shifting.  If the commercial plans didn’t exist, we would either have to take billions out of our inpatient facilities, or Medicare would have to pay substantially higher rates.  

 

Today’s NY Times has an article by Reed Abelsonon how health insurers are positioning themselves for health care reform. The article contrasts the approach of United Health Care, which boasts of diversifying its business, with Aetna, which promotes itself as a company that can actually influence the delivery of health care.

 

Without diversifying out of health insurance, how can health plans add value and continue to prosper in the coming years?

 

(1)Empower patients

Engaged patients who know about their illnesses and their medical care have better outcomes, and sometimes they even prevent medical errors.  Health plans are excellent at marketing, and know how to get the attention of their enrollees.

(2)Convert vast quantities of data into information to transform health care

Some commentators decry the inaccuracy and lack of timeliness of claims data.  But my experience is that claims information is very complete, since few providers fail to bill for their services. Unfortunately, electronic medical record data tends to be unstructured and is documented differently from system to system.

(3)Promote innovative payment methodologies for providers

The current predominately fee for service reimbursement encourages additional units of service, and does not encourage coordination of care.   Medicare is statutorily mandated to pay fee-for-service, and based on its size alone would have a hard time moving ambulatory care into episode based payment or capitation.  Health plans have to compete with each other for patients and for provider networks, and the existence of multiple competing insurers makes it more likely we will see innovation in payment methodology.  

(4)Develop selective networks

Medicare is too big to develop exclusive networks, and the political fallout from excluding a major hospital or a large group of physicians from Medicare would be huge.  Health insurers can develop selective networks for a broad range of patients, or can develop selective networks for narrow groups such as patients who require organ transplantation or inpatient behavioral health care.   Multiple competing insurers are key to this type of innovation.

(5)Transparency

Medicare made some substantial strides in promoting transparency over the last few years   But health plans have put dramatically more information on the web about provider quality.  Health plans should make their data available to state agencies or collaborative to do reporting, and should continue their efforts to educate their members about where to get the highest quality, cost-effective care.

(6)Promote evidence-based care

We have adequate evidence of the efficacy of too few medical decisions. But even where the evidence is in, our health care system remains unreliable.  We treat few diabetics to blood pressure, blood sugar, and cholesterol goal, and we send patients out of our offices with blood pressure which is often too high.  We miss vaccinations and cancer screenings. We give patients medications that are dangerous in combination, and medicines that are dangerous in the context of an individual patient’s coexisting medical illnesses.   Health plans should use claims and other data to identify opportunities to improve care for individuals and populations, and implement programs to alert providers and patients to opportunities to deliver better health care.

 

 

Health care reform will mean enormous changes – and much disruption in the health insurance market.  There will be plenty of opportunities for innovative health plans to add value and use their expertise to improve the quality and the cost-effectiveness of care.

 

 

 

The Impact of United Healthcare Settlement on Health Care Costs

Last week, New York Attorney General Andrew Cuomo announced that he had reached a settlement with United Health Group.   The insurer, which owns software company Ingenix, created the industry standard database which determines how much patients with PPO health plans will be reimbursed when they see "out of network" physicians.  Physician groups have long alleged that this database understates usual and customary fees, and have complained that the insurer has a conflict of interest since it benefits from a low fee schedule.  United agreed to pay  $50 million to help establish a university-run organization to establish an independent database, and admitted no wrongdoing.  Separately, United settled a class action suit over underreimbursement for $350 million. 

Here is how this works.  If I have a PPO and see a physician out of plan and she bills me $500, my insurer will check the Ingenix database. It that database suggests an appropriate price of $200 -- my health plan will only reimburse me 70% of $200 - leaving me with an effective bill of $360.   (Most out of plan benefits also have hefty deductibles - and if I paid the full $360, only $140 of this would be counted toward meeting the deductible.)

This is good consumer protection - since those with insurance usually thought they were purchasing coverage for 70% of the charge, not less than a third!  But how will this impact the cost of medical care? Like many things, it depends.

If providers successfully collected the entire billed fee from patients in this instance, this settlement will have no impact on aggregate cost - but merely shift that cost from out-of-pocket to health plan cost.   Health plans would have to raise their rates, but this would be offset by less consumer health spending.  

If providers routinely wrote off a portion of the consumer bill, though, this settlement would raise the overall cost of health care.  Many providers might add that they need to collect high fees from some payers to subsidize the care they deliver to others who cannot possibly afford to pay full freight.  This includes patients without insurance, and patients insured through state Medicaid programs that often use very low fee for service rates. 

This highlights an underlying problem.   There is a vast difference between billed charge, allowed charge, and actual payment. This difference disadvantages those without insurance coverage, and makes the actual cost of health care very opaque.